Role of renin–angiotensin system antagonists on long-term mortality post-percutaneous coronary intervention in reduced and preserved ejection fraction

Hamish C. Prosser, Kah Yong Peck, Diem Dinh, Louise Roberts, Jaya Chandrasekhar, Angela Brennan, Stephen J. Duffy, David Clark, Andrew E. Ajani, Ernesto Oqueli, Martin Sebastian, Christopher M. Reid, Melanie Freeman, Jithin K. Sajeev, Andrew W. Teh

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)


Aims: The use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II-receptor blockers (ARBs) post-myocardial infarction (MI) is supported by evidence based on trials performed in the thrombolysis era. This was prior to primary percutaneous coronary intervention (PCI) being routine practice, and with little direct evidence for the use of these medications in patients with preserved left ventricular (LV) function. This study sought to determine whether there is an association between ACEi/ARB use after PCI for acute coronary syndrome (ACS) and long-term all-cause mortality, with a particular focus on patients with preserved LV function. Methods: This multicentre, observational study evaluated prospectively collected data of 21,388 patients (> 18 years old) that underwent PCI for NSTEMI and STEMI between 2005 and 2018, and were alive at 30 day follow-up. Results: In total, 83.8% of patients were using ACEi/ARBs. Kaplan–Meier analysis demonstrated ACEi/ARB use was associated with a significantly lower mortality in the entire cohort (15.0 vs. 22.7%; p < 0.001) with a mean follow-up of 5.58 years; and independently associated with 24% lower mortality by Cox proportional hazards modelling (HR 0.76, CI 0.67–0.85, p < 0.001). ACEi/ARB therapy was also associated with significantly lower mortality in patients with reduced or preserved LV function, with greater survival benefit with worse LV dysfunction. Conclusion: ACEi/ARB therapy post-PCI is associated with significantly lower long-term mortality in patients with reduced and preserved LV function. These findings provide contemporary evidence for using these agents in the current era of routine primary PCI, including those with preserved EF. Graphical abstract: [Figure not available: see fulltext.]

Original languageEnglish
Pages (from-to)776-786
Number of pages11
JournalClinical Research in Cardiology
Issue number7
Publication statusPublished - Jul 2022


  • Angiotensin converting enzyme inhibitors
  • Angiotensin receptor blockers
  • Heart failure
  • Percutaneous coronary intervention

Cite this